Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TAKEDA PHARMACEUTICAL CO LTDTAK · Entity 2662 | President, Japan Pharma B.U. | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TAKEDA PHARMACEUTICAL CO LTD
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 4,500 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 1,500 · Balance 4,500 F1: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in three equal annual installments beginning on June 1, 2027. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2026-07-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-10 · Disposition to issuer · Disposed 1,022 · Balance 0 F2: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F3: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,882 to JPY 5,050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2027-06-01 | Direct | 1,392 |
Reported balance
After 2026-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-01 · Grant · Acquired 664 · Balance 1,392 F4: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2028-06-01 | Direct | 1,174 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Grant · Acquired 664 · Balance 1,174 F4: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
| Tax Obligation AwardSEC Table II · derivative / convertible security · Expires 2029-06-01 | Direct | 666 |
Reported balance
After 2026-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-01 · Grant · Acquired 666 · Balance 666 F4: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in three equal annual installments beginning on June 1, 2027.
F2: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10.
F3: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,882 to JPY 5,050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F4: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2026 Filed Jul 6, 2026 22:09 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | Disposition to issuerTax Obligation Award · Derivative | 1,022 | $4,931.40 | $5,039,890.80 |
DisclosureSEC source: 0001395064-26-000261 · wk-form4_1783375765.xml · derivative · entry 2 Miyabashira Asuka · CIK 0002111457 · President, Japan Pharma B.U. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,022 shares Expires 2026-06-01 F2 · derivative.exercise_price: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F2 · date: Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10. F3 · price: The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,882 to JPY 5,050, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:09 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 666 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000261 · wk-form4_1783375765.xml · derivative · entry 5 Miyabashira Asuka · CIK 0002111457 · President, Japan Pharma B.U. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 666 Underlying: Ordinary Shares · 666 shares Expires 2029-06-01 F4 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:09 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000261 · wk-form4_1783375765.xml · derivative · entry 4 Miyabashira Asuka · CIK 0002111457 · President, Japan Pharma B.U. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,174 Underlying: Ordinary Shares · 664 shares Expires 2028-06-01 F4 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:09 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantTax Obligation Award · Derivative | 664 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000261 · wk-form4_1783375765.xml · derivative · entry 3 Miyabashira Asuka · CIK 0002111457 · President, Japan Pharma B.U. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,392 Underlying: Ordinary Shares · 664 shares Expires 2027-06-01 F4 · derivative.exercise_price: Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 22:09 UTC | TAKEDA PHARMACEUTICAL CO LTD TAK · Entity 2662 | GrantOrdinary Shares | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001395064-26-000261 · wk-form4_1783375765.xml · nonDerivative · entry 1 Miyabashira Asuka · CIK 0002111457 · President, Japan Pharma B.U. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 F1 · kind: Represents an award of restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs vest in three equal annual installments beginning on June 1, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.